Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02990143 · ClinicalTrials.gov registry record · Phase 2
The Effectiveness of Ologen® Collagen Matrix in Preventing Intraocular Pressure (IOP) Spikes After Ahmed Glaucoma Valve Surgery (AGV-FP7)
A Phase 2 study, sponsored by The New York Eye & Ear Infirmary.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT02990143 is a Phase 2 study that was terminated before completion, run by The New York Eye & Ear Infirmary. The registered enrollment target is 30 participants.
The verdict
NCT02990143, a Phase 2 study, was terminated before completion, sponsored by The New York Eye & Ear Infirmary.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate whether placing Ologen over the posterior plate of the Ahmed glaucoma drainage device during initial implantation will allow the formation of a thinner capsule, and decrease the incidence and/or the extent of IOP elevation during the postoperative period.
Interventions
- PROCEDURE Ologen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-01-15 |
| Est. Completion | 2017-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02990143
The ClinicalTrials.gov registry entry for NCT02990143 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The New York Eye & Ear Infirmary, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ologen is the first listed.
NCT02990143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02990143 about?
NCT02990143 is a clinical study titled "The Effectiveness of Ologen® Collagen Matrix in Preventing Intraocular Pressure (IOP) Spikes After Ahmed Glaucoma Valve Surgery (AGV-FP7)". The purpose of this study is to investigate whether placing Ologen over the posterior plate of the Ahmed glaucoma drainage device during initial implantation will allow the formation of a thinner capsule, and decrease the incidence and/or the extent of IOP elevation during the postoperative period.
What is the current status of trial NCT02990143?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2014-01-15. Estimated completion is 2017-12-15.
What interventions are being tested in trial NCT02990143?
The interventions under investigation include: Ologen (PROCEDURE).
Who is sponsoring clinical trial NCT02990143?
This trial is sponsored by The New York Eye & Ear Infirmary, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.